Movement Disorder News and Research

Latest Movement Disorder News and Research

Journal highlights toxic nature of herbal medicines

A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.

9 Feb 2010

New revolutionary treatment for patients suffering from movement disorders

Deep Brain Stimulation (DBS), a new treatment being offered at Geisinger Medical Center (GMC) and Geisinger Wyoming Valley Medical Center (GWV), can dramatically reduce symptoms of movement disorders.

9 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

Simulation training may help improve driving skills of Parkinson's disease patients

In a first-of-its-kind study, Medical College of Georgia researchers are testing whether simulation driving can reduce Parkinson's patients' threefold increased risk of car accidents.

2 Feb 2010

CAMH signs licensing agreement to develop and market genetic test for degenerative muscle disorder

The Centre for Addiction and Mental Health (CAMH) has signed a licensing agreement with a Massachusetts firm to develop and market an innovative genetic test for a recently identified degenerative muscle disorder. The disorder tends to strike adults in their early 30s.

From Thermo Fisher Scientific Inc. 29 Jan 2010

Large research gap exists in effectiveness, mechanism and safety of drugs in children

Only a few anti-spasticity medications used for children with cerebral palsy are backed by sufficient research to justify their use, according to a new review of scientific literature headed by a UT Southwestern Medical Center neurologist and conducted by a national panel of interdisciplinary experts nationwide.

27 Jan 2010

Scott & White conducts DBS research for Parkinson's patients

At Scott & White Memorial Hospital, a multi-disciplinary team of neurosurgeons, neurologists, neurophysiologist, neuropsychologists and a movement disorders specialist are offering hope to some Parkinson's patients with a treatment called Deep Brain Stimulation (DBS). DBS involves placing a thin wire that carries electrical currents deep within the brain on Parkinson's patients who are no longer benefitting from medications, and have significant uncontrollable body movements called dyskinesia. Scott & White is also performing research into the effects of DBS on the non-motor symptoms of Parkinson's disease including "drenching sweats," bladder dysfunction, depression, hallucination, anxiety, and dementia as well as intestinal disorders, loss of sense of smell, and sleep disturbances.

27 Jan 2010

New computational model helps understand how dopamine medications affect non-motor functions

A new brain-based computational model is helping to understand how Parkinson's disease and dopamine medications-used to treat motor symptoms caused by the disease- can affect learning and attention.

21 Jan 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

Neurosurgeons perform world's first operation on 'habenula' to treat depression

A team of neurosurgeons at Heidelberg University Hospital and psychiatrists at the Central Institute of Mental Health, Mannheim have for the first time successfully treated a patient suffering from severe depression by stimulating the habenula, a tiny nerve structure in the brain.

8 Jan 2010

DSPA submits lurasidone NDA to the FDA

Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients.

4 Jan 2010

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

Second-quarter fiscal 2010 results announced by Medtronic

Medtronic, Inc. today announced financial results for its second quarter of fiscal year 2010, which ended Oct. 30, 2009.

24 Nov 2009

Multidisciplinary pediatric neurosurgery program launched

Responding to a growing need in central and northeast Pennsylvania for highly specialized care of pediatric brain tumors and other central nervous system disorders, Geisinger's Janet Weis Children's Hospital has launched a state-of-the-art and comprehensive pediatric neurosurgery program. The multidisciplinary program is led by pediatric neurosurgeon Amir Kershenovich, M.D., who says he is pleased to accept his challenging role.

24 Nov 2009

CleveMed to distribute its products in Europe and Canada following receipt of the CE Mark and CMDCAS

CleveMed recently received ISO 13485 certification issued by BSI Management Systems America Inc., one of the foremost auditing bodies in the world. CleveMed has also received the CE Mark and CMDCAS allowing its products to be distributed to the large European and the Canadian markets which will strengthen its worldwide market presence.

19 Nov 2009

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Today, Merz Pharmaceuticals announced Xeomin®, the first botulinum toxin type A free from complexing proteins has been granted an extension of indication for post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adults in various European countries.

19 Nov 2009

Stereotactic radiosurgery effective in eliminating Parkinson's disease tremors

Stereotactic radiosurgery (SRS) offers a less invasive way to eliminate tremors caused by Parkinson's disease and essential tremor than deep brain stimulation (DBS) and radiofrequency (RF) treatments, and is as effective, according to a long-term study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Movement Disorder News and Research

Latest Movement Disorder News and Research

Journal highlights toxic nature of herbal medicines

New revolutionary treatment for patients suffering from movement disorders

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

Simulation training may help improve driving skills of Parkinson's disease patients

CAMH signs licensing agreement to develop and market genetic test for degenerative muscle disorder

Large research gap exists in effectiveness, mechanism and safety of drugs in children

Scott & White conducts DBS research for Parkinson's patients

New computational model helps understand how dopamine medications affect non-motor functions

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

Neurosurgeons perform world's first operation on 'habenula' to treat depression

DSPA submits lurasidone NDA to the FDA

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Second-quarter fiscal 2010 results announced by Medtronic

Multidisciplinary pediatric neurosurgery program launched

CleveMed to distribute its products in Europe and Canada following receipt of the CE Mark and CMDCAS

Xeomin receives approval for post-stroke spasticity of upper limb in European countries

Stereotactic radiosurgery effective in eliminating Parkinson's disease tremors

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

MSU receives $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease grant

Clinical trial of gene transfer therapy for advanced Parkinson's disease

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Movement Disorder News and Research

Latest Movement Disorder News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in